Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics
SLGL Price/Volume Stats
|Current price||$1.25||52-week high||$5.71|
|Prev. close||$1.38||52-week low||$1.16|
|Day high||$1.39||Avg. volume||13,068|
|50-day MA||$1.52||Dividend yield||N/A|
|200-day MA||$2.98||Market Cap||28.91M|
SLGL Stock Price Chart Interactive Chart >
Sol-Gel Technologies Ltd. (SLGL) Company Bio
Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel
SLGL Latest News Stream
|Loading, please wait...|
SLGL Latest Social Stream
View Full SLGL Social Stream
Latest SLGL News From Around the Web
Below are the latest news stories about SOL-GEL TECHNOLOGIES LTD that investors may wish to consider to help them evaluate SLGL as an investment opportunity.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Sol-Gel Technologies fair value estimate is US$1.87 Sol-Gel...
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains cash runway into the second half of 2025 NESS ZIONA, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved
Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies
Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies are part of the Zacks Industry Outlook article.
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, AMPH and SLGL.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
SLGL Price Returns
Continue Researching SLGLWant to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:
Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch